Tachycardia, VentricularRASA-VTNCT03779165
R Wave Sensing After VT Ablation
An observational study of Tachycardia, Ventricular and Catheter Ablation, run by University Hospital Sestre Milosrdnice at 4 sites in 2 countries.
Trial summary
Sustained, monomorphic ventricular tachycardia (VT) is most commonly encountered in patients with structural heart disease, usually with ischemic aetiology. It has been proven that repeated episodes of sustained VT contribute to the mortality of patients with structural heart disease. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Tachycardia, Ventricular, Catheter Ablation, Follow-Up Studies
- How many people
- 100 participants
- Where
- 4 sitesin 2 countries
- Study dates
- Dec 2018to Dec 2020
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with structural heart disease (ischemic and non-ischemic aetiology) implanted with implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy cardioverter defibrillator (CRT-D) and recurrent, sustained, monomorphic ventricular tachycardia, who are, according to their cardiologist, planned for 3D mapping and radiofrequency ablation of ventricular tachycardia myocardial substrate.
Who may be able to join
- patients with recurrent, sustained ventricular tachycardia
- patients implanted with implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy cardioverter defibrillator (CRT-D)
- patients planned for 3D mapping and radiofrequency ablation of ventricular tachycardia myocardial substrate
- patients who are able to understand and sign informed consent
Who cannot join
- Patients with combined mechanical aortic and mitral valve prostheses
- Patients with RF ablation of VT done in the last 12 months
- Patients with known damaged ICD/CRT-D electrode or battery
- Patients undergoing VT ablation who have not been implanted with ICD or CRT-D
- Patients not willing or able to undergo clinical follow-up of ICD/CRT-D device
- Patients with life expectancy < 1 year
- Not able to understand or willing to sign informed consent
- Age < 18 years
Trial locations and contacts
4 sites in 2 countries.
4 sites in 2 countries
Croatia2 sites
University Hospital Rijeka
Rijeka, 51000
Sandro Brusich, MD, 0038551658111, sandro.brusich@gmail.com
University Hospital Sestre milosrdnice
Zagreb, 10000
Ivan Zeljkovic, MD, 0038513787733, ivanzeljkov@gmail.com
Switzerland2 sites
University Hospital Basel
Basel, 4031
Christian Sticherling, MD, +41 61 265 44 44, christian.sticherling@usb.ch
University Hospital Bern
Bern, 3012
About this study
Official title: R Wave Sensing After Radiofrequency Ablation of Ventricular Tachycardia Substrate in Patients With Structural Heart Disease
Sustained, monomorphic ventricular tachycardia (VT) is most commonly encountered in patients with structural heart disease, usually with ischemic aetiology. It has been proven that repeated episodes of sustained VT contribute to the mortality of patients with structural heart disease. These patients are usually implanted with implantable cardioverter defibrillator without (ICD) or with cardiac resynchronisation therapy (CRT-D). According to the current guidelines 3D mapping with radiofrequency (RF) ablation of the tachycardia substrate is an established therapeutic option. As part of the clinical follow-up of patients implanted with cardiac implantable electronic devices (CIED), CIED function parameters are monitored every 6 months, which is always done before and after any procedure involving RF ablation. Furthermore, a transient drop of R wave sensing has been demonstrated after the atrioventricular (AV) node ablation in patients with single-chamber pacemakers and fast atrial fibrillation. The aim of this study is to assess the change in R wave sensing after the RF ablation of VT substrate.
This study will be performed as a clinical, prospective, multi-centre, observational cohort study with a structured follow-up period of 12 months. All consecutive patients with sustained VT implanted with ICD or CRT-D undergoing RF ablation procedure of myocardial substrate, who are able to understand and sign informed consent, will be enrolled. Primary objective is a R wave sensing drop > 30% after VT substrate ablation procedure. Recruiting should not exceed 12 months with the minimal follow-up period of 12 months (24 months in total). Standardized statistical methods and test will be done using SPSS Software Version 22.0 or newer.
This unique study offers the possibility to show the impact of RF ablation on short-term and long-term R wave sensing change assessed by ICD or CRT-D's ventricle electrode in patients with sustained VT and structural heart disease undergoing ablation procedure. This observational data is needed to further refine the treatment of these patients and to prevent possible ICD/CRT-D dysfunction which could endanger this patient population.
Read the detailed description
Sustained, monomorphic ventricular tachycardia (VT) is most commonly encountered in patients with structural heart disease, usually with ischemic aetiology. It has been proven that repeated episodes of sustained VT contribute to the mortality of patients with structural heart disease. These patients are usually implanted with implantable cardioverter defibrillator without (ICD) or with cardiac resynchronisation therapy (CRT-D) as part of sudden cardiac death (SCD) prevention and have had activation of the device due to the sustained VT episodes. According to the current guidelines 3D mapping with radiofrequency (RF) ablation of the tachycardia substrate is an established therapeutic option. As part of the clinical follow-up of patients implanted with cardiac implantable electronic devices (CIED), including ICDs and CRT-Ds, function parameters are monitored every 6 months. The same check-up is done before and after any procedure involving RF ablation. Furthermore, a transient drop of R wave sensing has been demonstrated after the RF ablation of the atrioventricular (AV) node in patients with uncontrollable fast atrial fibrillation implanted with single-chamber pacemakers. The above mentioned have not been studied yet in patients ablated due to sustained VT. Hence, the aim of this study is to assess the change in R wave sensing after the RF ablation of VT substrate in patients with structural heart disease.
This study will be performed as a clinical, prospective, multi-centre, observational (analytic, longitudinal) cohort study with patient enrolment in 4 electrophysiology centres in Croatia and Switzerland and a structured follow-up period of 12 months.
All consecutive patients with sustained VT implanted with ICD or CRT-D undergoing RF ablation procedure of myocardial substrate, who are able to understand and sign informed consent, will be enrolled.
Exclusion criteria:
- Patients with combined mechanical aortic and mitral valve prostheses
- Patients with RF ablation of VT done in the last 12 months
- Patients with known damaged ICD/CRT-D electrode or battery
- Patients undergoing VT ablation who have not been implanted with ICD or CRT-D
- Patients not willing or able to undergo clinical follow-up of ICD/CRT-D device
- Patients with life expectancy < 1 year
- Not able to understand or willing to sign informed consent
- Age < 18 years Primary objective is a R wave sensing drop > 30% after VT substrate ablation procedure.
Specific (secondary) end-points:
- incidence of VT recurrence after the ablation procedure;
- risk factors for R wave sensing drop (> 30%) after the RF ablation of VT substrate;
- time needed for R wave sensing recovery after the RF ablation procedure. Recruiting should not exceed 12 months with the minimal follow-up period of 12 months (24 months in total).
The risk categorisation of the study was done and the study was awarded a risk category A.
Sample size was chosen according to annual procedure volumes in Croatia and Switzerland. In addition, it is confirmed by power test (number needed to recruit: 52). Recruiting should not exceed 12 months. Categorical variables will be presented by contingency tables in absolute values and percentages. Categorical variables will be compared by the chi-square with Yates corrections or Fisher's exact test. Continuous data will be expressed as means and standard deviations or median with corresponding interquartile range. The differences in quantitative variables will be tested by Mann-Whitney U-test (non-parametric test for independent samples). Logistic regression will be used to analyse the association between all variables of interest and the R wave sensing drop. Multivariate logistic regression will be used to adjust for confounding factors. Predictors of the R wave sensing drop will be assessed in a univariate and multivariate Cox proportional hazards model. The statistical analysis will be done using SPSS Software Version 22.0 or newer (IBM SPSS Statistics, New York, USA).
This unique study offers the possibility to show the impact of RF ablation on short-term and long-term R wave sensing change assessed by ICD or CRT-D's ventricle electrode in patients with sustained VT and structural heart disease undergoing ablation procedure. This observational data is needed to further refine the treatment of these patients and to prevent possible ICD/CRT-D dysfunction which could endanger this patient population. Despite a high number of cohort registries for cardiovascular diseases (e.g. Danish heart registry, ORBIT-AF, GARFIELD AF registry, Swiss AF registry), there are scarce data on patients with structural VT and no data regarding R wave sensing changes influenced by RF energy application in ventricles. In addition, this could influence obligatory rhythm-monitoring duration and consequently hospitalization duration of patients with VT undergoing RF ablation procedures. Apart from the above mentioned, in those patients with non-optimal preprocedural R wave sensing, this could mean contraindication for procedure or having the need to do postprocedural defibrillation testing. It is likely, that data from our study will lead to future changes in periprocedural planning and modalities.
This study will be conducted in compliance with the current version of the Declaration of Helsinki, the ICH-GCP or ISO EN 14155 (as far as applicable) as well as all national legal and regulatory requirements. According to ethical regulations, the study plan with the proposed participant information and consent form as well as other project-specific documents will be submitted to Ethic committee of the participating centres.
- Keywords
- ventricular tachycardia, R wave; sensing, radiofrequency ablation, follow-up
- Medical subject headings
- Tachycardia, Ventricular
What is being measured
The primary outcome is the main question the study is designed to answer.
R wave sensing change
R wave sensing drop > 30% after RF ablation of VT substrate in left and/or right ventricle assessed by ventricular electrode of the CIED
Measured: immediately after the ablation procedure
Secondary outcomes (5)
R wave sensing change 24h follow-up
R wave sensing drop > 30% after RF ablation of VT substrate in left and/or right ventricle assessed by ventricular electrode of the CIED
Measured: 24 hours after ablation procedure
R wave sensing change 3-6 month follow-up
R wave sensing drop > 30% after RF ablation of VT substrate in left and/or right ventricle assessed by ventricular electrode of the CIED
Measured: 3-6 months after ablation procedure
R wave sensing change 9-12 month follow-up
R wave sensing drop > 30% after RF ablation of VT substrate in left and/or right ventricle assessed by ventricular electrode of the CIED
Measured: 9-12 months after the ablation procedure
Incidence of VT recurrence after the ablation procedure
Assessing the VT recurrence after the ablation procedure by ICD or CRT-D interrogation adn function testing
Measured: 12 months after the ablation procedure
Risk factors for R wave sensing change after the RF ablation of VT substrate
assessing risk factors for R wave sensing drop after the RF ablation of VT substrate
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Dec 2018
- Study startDec 2018 (estimated)
- Primary completionDec 2019 (estimated)
- Study completionDec 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Tachycardia, VentricularStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- University Hospital Sestre Milosrdnice
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ivan Zeljkovic, University Hospital Sestre Milosrdnice
- Investigators
- Ivan Zeljkovic, MD, Principal investigator, University Hospital Sestre Milosrdnice
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03779165
- Sponsor's protocol ID
- ZAPSA01
- Other IDs
- UTN U1111-1223-2331
- Acronym
- RASA-VT
- Status last verified
- Dec 2018
- First submitted
- 17 Dec 2018
- Last updated
- 20 Dec 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Darrat YH, Agarwal A, Morales GX, Thompson J, Abdel-Latif A, Waespe K, DI Biase L, Natale A, Patwardan A, Elayi CS. Radiofrequency and Cryo-Ablation Effect on Transvenous Pacing and Defibrillatory Lead Integrity: An In Vitro Study. J Cardiovasc Electrophysiol. 2016 Aug;27(8):976-80. doi: 10.1111/jce.13007. Epub 2016 Jun 14.
PubMed 27138905Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ; Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace. 2015 Nov;17(11):1601-87. doi: 10.1093/europace/euv319. Epub 2015 Aug 29. No abstract available.
PubMed 26318695
Study at a glance
From the registry record, last updated by the sponsor on 20 Dec 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- R Wave Sensing After Radiofrequency Ablation of Ventricular Tachycardia Substrate in Patients With Structural Heart Disease
- ClinicalTrials.gov ID
- NCT03779165
- Acronym / sponsor ID
- RASA-VT / ZAPSA01
- Keywords
- ventricular tachycardia, R wave; sensing, radiofrequency ablation, follow-up
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University Hospital Sestre MilosrdniceUniversity, hospital or other
- Study start
- Dec 2018 (estimated)
- Primary completion
- Dec 2019 (estimated)
- Study completion
- Dec 2020 (estimated)
- First posted
- 19 Dec 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sustained, monomorphic ventricular tachycardia (VT) is most commonly encountered in patients with structural heart disease, usually with ischemic aetiology. It has been proven that repeated episodes of sustained VT contribute to the mortality of patients with structural heart disease. These patients are usually implanted with implantable cardioverter defibrillator without (ICD) or with cardiac resynchronisation therapy (CRT-D). According to the current guidelines 3D mapping with radiofrequency (RF) ablation of the tachycardia substrate is an established therapeutic option. As part of the clinical follow-up of patients implanted with cardiac implantable electronic devices (CIED), CIED function parameters are monitored every 6 months, which is always done before and after any procedure involving RF ablation. Furthermore, a transient drop of R wave sensing has been demonstrated after the atrioventricular (AV) node ablation in patients with single-chamber pacemakers and fast atrial fibrillation. The aim of this study is to assess the change in R wave sensing after the RF ablation of VT substrate.
This study will be performed as a clinical, prospective, multi-centre, observational cohort study with a structured follow-up period of 12 months. All consecutive patients with sustained VT implanted with ICD or CRT-D undergoing RF ablation procedure of myocardial substrate, who are able to understand and sign informed consent, will be enrolled. Primary objective is a R wave sensing drop > 30% after VT substrate ablation procedure. Recruiting should not exceed 12 months with the minimal follow-up period of 12 months (24 months in total). Standardized statistical methods and test will be done using SPSS Software Version 22.0 or newer.
This unique study offers the possibility to show the impact of RF ablation on short-term and long-term R wave sensing change assessed by ICD or CRT-D's ventricle electrode in patients with sustained VT and structural heart disease undergoing ablation procedure. This observational data is needed to further refine the treatment of these patients and to prevent possible ICD/CRT-D dysfunction which could endanger this patient population.
Detailed description
Sustained, monomorphic ventricular tachycardia (VT) is most commonly encountered in patients with structural heart disease, usually with ischemic aetiology. It has been proven that repeated episodes of sustained VT contribute to the mortality of patients with structural heart disease. These patients are usually implanted with implantable cardioverter defibrillator without (ICD) or with cardiac resynchronisation therapy (CRT-D) as part of sudden cardiac death (SCD) prevention and have had activation of the device due to the sustained VT episodes. According to the current guidelines 3D mapping with radiofrequency (RF) ablation of the tachycardia substrate is an established therapeutic option. As part of the clinical follow-up of patients implanted with cardiac implantable electronic devices (CIED), including ICDs and CRT-Ds, function parameters are monitored every 6 months. The same check-up is done before and after any procedure involving RF ablation. Furthermore, a transient drop of R wave sensing has been demonstrated after the RF ablation of the atrioventricular (AV) node in patients with uncontrollable fast atrial fibrillation implanted with single-chamber pacemakers. The above mentioned have not been studied yet in patients ablated due to sustained VT. Hence, the aim of this study is to assess the change in R wave sensing after the RF ablation of VT substrate in patients with structural heart disease.
This study will be performed as a clinical, prospective, multi-centre, observational (analytic, longitudinal) cohort study with patient enrolment in 4 electrophysiology centres in Croatia and Switzerland and a structured follow-up period of 12 months.
All consecutive patients with sustained VT implanted with ICD or CRT-D undergoing RF ablation procedure of myocardial substrate, who are able to understand and sign informed consent, will be enrolled.
Exclusion criteria:
- Patients with combined mechanical aortic and mitral valve prostheses
- Patients with RF ablation of VT done in the last 12 months
- Patients with known damaged ICD/CRT-D electrode or battery
- Patients undergoing VT ablation who have not been implanted with ICD or CRT-D
- Patients not willing or able to undergo clinical follow-up of ICD/CRT-D device
- Patients with life expectancy < 1 year
- Not able to understand or willing to sign informed consent
- Age < 18 years Primary objective is a R wave sensing drop > 30% after VT substrate ablation procedure.
Specific (secondary) end-points:
- incidence of VT recurrence after the ablation procedure;
- risk factors for R wave sensing drop (> 30%) after the RF ablation of VT substrate;
- time needed for R wave sensing recovery after the RF ablation procedure. Recruiting should not exceed 12 months with the minimal follow-up period of 12 months (24 months in total).
The risk categorisation of the study was done and the study was awarded a risk category A.
Sample size was chosen according to annual procedure volumes in Croatia and Switzerland. In addition, it is confirmed by power test (number needed to recruit: 52). Recruiting should not exceed 12 months. Categorical variables will be presented by contingency tables in absolute values and percentages. Categorical variables will be compared by the chi-square with Yates corrections or Fisher's exact test. Continuous data will be expressed as means and standard deviations or median with corresponding interquartile range. The differences in quantitative variables will be tested by Mann-Whitney U-test (non-parametric test for independent samples). Logistic regression will be used to analyse the association between all variables of interest and the R wave sensing drop. Multivariate logistic regression will be used to adjust for confounding factors. Predictors of the R wave sensing drop will be assessed in a univariate and multivariate Cox proportional hazards model. The statistical analysis will be done using SPSS Software Version 22.0 or newer (IBM SPSS Statistics, New York, USA).
This unique study offers the possibility to show the impact of RF ablation on short-term and long-term R wave sensing change assessed by ICD or CRT-D's ventricle electrode in patients with sustained VT and structural heart disease undergoing ablation procedure. This observational data is needed to further refine the treatment of these patients and to prevent possible ICD/CRT-D dysfunction which could endanger this patient population. Despite a high number of cohort registries for cardiovascular diseases (e.g. Danish heart registry, ORBIT-AF, GARFIELD AF registry, Swiss AF registry), there are scarce data on patients with structural VT and no data regarding R wave sensing changes influenced by RF energy application in ventricles. In addition, this could influence obligatory rhythm-monitoring duration and consequently hospitalization duration of patients with VT undergoing RF ablation procedures. Apart from the above mentioned, in those patients with non-optimal preprocedural R wave sensing, this could mean contraindication for procedure or having the need to do postprocedural defibrillation testing. It is likely, that data from our study will lead to future changes in periprocedural planning and modalities.
This study will be conducted in compliance with the current version of the Declaration of Helsinki, the ICH-GCP or ISO EN 14155 (as far as applicable) as well as all national legal and regulatory requirements. According to ethical regulations, the study plan with the proposed participant information and consent form as well as other project-specific documents will be submitted to Ethic committee of the participating centres.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 12 Months
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with structural heart disease (ischemic and non-ischemic aetiology) implanted with implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy cardioverter defibrillator (CRT-D) and recurrent, sustained, monomorphic ventricular tachycardia, who are, according to their cardiologist, planned for 3D mapping and radiofrequency ablation of ventricular tachycardia myocardial substrate.
Key inclusion criteria (4 listed)
- patients with recurrent, sustained ventricular tachycardia
- patients implanted with implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy cardioverter defibrillator (CRT-D)
- patients planned for 3D mapping and radiofrequency ablation of ventricular tachycardia myocardial substrate
- patients who are able to understand and sign informed consent
Key exclusion criteria (8 listed)
- Patients with combined mechanical aortic and mitral valve prostheses
- Patients with RF ablation of VT done in the last 12 months
- Patients with known damaged ICD/CRT-D electrode or battery
- Patients undergoing VT ablation who have not been implanted with ICD or CRT-D
- Patients not willing or able to undergo clinical follow-up of ICD/CRT-D device
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
R wave sensing change
Time frame: immediately after the ablation procedure
R wave sensing drop > 30% after RF ablation of VT substrate in left and/or right ventricle assessed by ventricular electrode of the CIED
5 secondary outcomes
R wave sensing change 24h follow-up
Time frame: 24 hours after ablation procedure
R wave sensing change 3-6 month follow-up
Time frame: 3-6 months after ablation procedure
R wave sensing change 9-12 month follow-up
Time frame: 9-12 months after the ablation procedure
Incidence of VT recurrence after the ablation procedure
Time frame: 12 months after the ablation procedure
Risk factors for R wave sensing change after the RF ablation of VT substrate
Time frame: 12 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Dec 2018.
- Results publication: PubMed 27138905Darrat YH, Agarwal A, Morales GX, Thompson J, Abdel-Latif A, Waespe K, DI Biase L, Natale A, Patwardan A, Elayi CS. Radiofrequency and Cryo-Ablation Effect on Transvenous Pacing and Defibrillatory Lead Integrity: An In Vitro Study. J Cardiovasc Electrophysiol. 2016 Aug;27(8):976-80. doi: 10.1111/jce.13007. Epub 2016 Jun 14.
- Results publication: PubMed 26318695Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ; Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace. 2015 Nov;17(11):1601-87. doi: 10.1093/europace/euv319. Epub 2015 Aug 29. No abstract available.
- Individual participant dataSharing planned: No
Related trials for Tachycardia, Ventricular
Enrolling by invitation
VINTAGE (Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms) Using Commercial Off-The-Shelf (COTS) Catheters
Ventricular Arrhythmia
Not yet recruiting
MRI-guided Ventricular Tachycardia Ablation in Patients With Structural Heart Disease
Ventricular Tachycardia (VT), Ischemic Cardiomyopathy
Recruiting
Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)
Ventricular Tachycardia
RecruitingPhase 1
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Catecholaminergic Polymorphic Ventricular Tachycardia
Recruiting
SPIKE FLOW Endocardial Lead Safety and Performance Study
Acute Myocardial Infarction (AMI), Asystole
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ivan Zeljkovic, MD principal investigator
University Hospital Sestre Milosrdnice
4 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Tachycardia, Ventricular and Catheter Ablation, run by University Hospital Sestre Milosrdnice at 4 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Croatia, Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Ivan Zeljkovic, MD (0038513787733, ivanzeljkov@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
R wave sensing change (time frame: immediately after the ablation procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03779165, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2018.